Cellulitishttps://en.wikipedia.org/wiki/Cellulitis
Cellulitis bụ ọrịa na-efe efe nke na-emetụta akụkụ dị n'ime akpụkpọ ahụ. Dị ka ihe ịrịba ama na mgbaàmà, mpaghara na-egbu mgbu nke ọbara ọbara na-abawanye n'ogo n'ime ụbọchị ole na ole. A naghị akọwapụta oke mpaghara mpaghara ọbara ọbara nke ọma yana akpụkpọ ahụ nwere ike ịza. Ebe a na-ebute ọrịa na-egbukarị mgbu. Onye ahụ nwere ike ịnwe ahụ ọkụ na mygia.

Ụkwụ na ihu bụ saịtị kachasị emetụta. Ihe ndị nwere ike ịkpata nsogbu gụnyere oke ibu, ọzịza ụkwụ, na ịka nká. Nje bacteria na-emekarị bụ streptococci na Staphylococcus aureus.

A na-ejikarị ọgwụ nje eme ihe n'ọnụ, dị ka cephalexin, amoxicillin ma ọ bụ cloxacillin. Ihe dị ka 95% nke ndị mmadụ na-aka mma mgbe ọgwụgwọ 7 ruo 10 gasịrị. Otú ọ dị, ndị na-arịa ọrịa shuga na-enwekarị ihe ka njọ.

Cellulitis bụ nsogbu a na-ahụkarị, na United Kingdom, cellulitis bụ ihe kpatara 1.6% nke nnabata n'ụlọ ọgwụ. Cellulitis na 2015 butere ihe dị ka ọnwụ 16,900 n'ụwa niile.

Ọgwụgwọ - Ọgwụ OTC
Cellulitis dị elu chọrọ ọgwụgwọ na ọgwụ nje naanị dọkịta nyere ya. Ọ bụrụ na ọnya ahụ na-aga n'ihu ngwa ngwa ma na-esonyere ya na ahụ ọkụ na oyi, ọ dị mma ịhụ dọkịta ozugbo enwere ike.
Itinye ude ọgwụ nje na-abụghị ọgwụ na ọnya mbụ nwere ike inye aka. Ọ bụrụ na etinyere ude ahụ nke ukwuu, ọ nwere ike ọ gaghị arụ ọrụ ma ọlị.
#Polysporin
#Bacitracin
#Betadine

Jiri ihe mgbu OTC dị ka acetaminophen mee ka mgbu ahụ dị mfe.
#Ibuprofen
#Naproxen
#Acetaminophen

Debe ụkwụ ọcha ma na-agwọ ụkwụ ndị na-eme egwuregwu n'ihi na ụkwụ ndị na-eme egwuregwu na-abawanye ohere nke cellulitis.

Ọgwụgwọ
#First-generation cephalosporins (e.g. Cefradine)
#Bacterial culture
#Third-generation cephalosporins (e.g. Cefditoren Pivoxil)
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
  • Ụkwụ bụ ebe a na-ahụkarị maka Cellulitis.
  • Okwu ikpe
  • Cellulitis - ọkwa ọgwụgwọ
  • Cellulitis n'ụkwụ aka ekpe. Ọ bụrụ na ọ na-agbasa ebe niile, nnukwu ahụ ọkụ nwere ike ime, na-eduga n'ihe egwu septic na-eyi ndụ egwu.
  • Mgbe ọnya ahụ na-akawanye mma, hyperpigmentation post-inflammatory nwere ike ịpụta.
  • Enwere ike ime ya site na ọnya dị n'ọbụ aka.
  • Okwu ikpe
  • Ọ bụrụ na patch erythematous dị nro gbasaa ngwa ngwa, Cellulitis kwesịrị ka enyo ya enyo.
  • Ka Cellulitis na-akawanye mma, mkpụrụ ndụ akpụkpọ ahụ nwụrụ anwụ nwere ike ịpụpụ, ọ nwekwara ike ịfụ ụfụ.
  • Ọtụtụ Cellulitis na-esonyere ya na ọzịza na erythema na mpaghara gbara ya gburugburu. Agbanyeghị, n'ọnọdụ a pụrụ iche ebe enweghị erythema gbara ya gburugburu, a ga-enyokwa enyo carcinoma squamous cell.
  • Okwu ikpe
  • Oge ọgwụgwọ.
References Cellulitis 31747177 
NIH
Cellulitis bụ ọrịa akpụkpọ anụ na-ebutekarị. Ọ na-emetụta ihe karịrị nde mmadụ 14 kwa afọ na United States. Ọ na-eduga ihe dị ka ijeri $3. 7 na ụgwọ nlekọta ụgbọ ala yana ụlọ ọgwụ 650,000 kwa afọ. Na-emekarị, cellulitis na-egosi dị ka ebe na-ekpo ọkụ, na-acha uhie uhie na akpụkpọ ahụ na ọzịza na ịdị nro. Ọ na-ebute ya site na ọrịa nje na mberede nke na-ebute mbufụt n'ígwé akpụkpọ anụ na anụ ahụ dị nso. Enweghị ọzịza ma ọ bụ ọtụ nwere ọrịa a. Beta-hemolytic streptococci, karịsịa otu A streptococcus (Streptococcus pyogenes) , bụ ndị na-emebu eme ihe, na-esote methicillin-sensitive Staphylococcus aureus.
Cellulitis is a common bacterial skin infection, with over 14 million cases occurring in the United States annually. It accounts for approximately 3.7 billion dollars in ambulatory care costs and 650000 hospitalizations annually. Cellulitis typically presents as a poorly demarcated, warm, erythematous area with associated edema and tenderness to palpation. It is an acute bacterial infection causing inflammation of the deep dermis and surrounding subcutaneous tissue. The infection is without an abscess or purulent discharge. Beta-hemolytic streptococci typically cause cellulitis, generally group A streptococcus (i.e., Streptococcus pyogenes), followed by methicillin-sensitive Staphylococcus aureus. Patients who are immunocompromised, colonized with methicillin-resistant Staphylococcus aureus, bitten by animals, or have comorbidities such as diabetes mellitus may become infected with other bacteria.
 Cellulitis: current insights into pathophysiology and clinical management 29219814
Cellulitis bụ ọrịa nje na-ebute n'ahụ na anụ ahụ dị nro. Ọ na-eme mgbe enwere nsogbu na mgbochi nke akpụkpọ ahụ, usoro ahụ ji alụso ọrịa ọgụ, ma ọ bụ mgbasa ọbara. Ọrịa shuga, oke ibu, na ịka nká na-abawanye ohere nke cellulitis site n'imetu ebe ndị a. Anyị na-elekwa anya n'oge na-adịbeghị anya nchoputa na nchọpụta cellulitis , na-akọwapụta mkpa ọ dị nrịbama ziri ezi ebe ọ bụ na ọnọdụ ndị dị ka venous insufficiency, eczema, deep vein thrombosis, na gout na-enwekarị mgbagwoju anya na cellulitis. A na-ahọrọ ọgwụ nje ndị a na-eji na-agwọ cellulitis nke ọma ka ha lekwasị anya na nje bacteria na-enweghị agbamume ọgwụ mgbochi. Anyị na-ekwukwa maka ọgwụ nje ọhụrụ akwadoro maka cellulitis. Cellulitis na-alọghachikarị n'ihi ihe ize ndụ na-aga n'ihu na mmebi nke sistemu lymphatic.
Cellulitis is a bacterial infection of the skin and soft tissues. It happens when there are issues with the skin's protective barrier, the immune system, or blood circulation. Diabetes, obesity, and old age increase the chances of cellulitis by affecting these areas. We also look at recent findings on diagnosing cellulitis, highlighting the importance of accurate diagnosis since conditions like venous insufficiency, eczema, deep vein thrombosis, and gout are often confused with cellulitis. Antibiotics used to treat cellulitis are chosen carefully to target common bacteria without encouraging antibiotic resistance. We also talk about new antibiotics approved for cellulitis. Cellulitis often comes back because of ongoing risk factors and damage to the lymphatic system..
 Current Treatment Options for Acute Skin and Skin-structure Infections 30957166 
NIH
Ọtụtụ ndị mmadụ na-aga ụlọ ọgwụ ma ọ bụ ụlọ mberede maka ọrịa akpụkpọ anụ na mberede. Staphylococcus aureus bụ nje bụ́ isi na-ebute ọrịa ndị a, ọ na-esikwa ike ịgwọta ya n'ihi na ụdị ụfọdụ na-eguzogide ọgwụ nje a na-ahụkarị.
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
 Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus 32257966 
NIH
Enwere ike kewaa Staphylococcus aureus ụzọ abụọ dabere na nzaghachi ha na ọgwụ nje: methicillin-sensitive Staphylococcus aureus (MSSA) , methicillin-resistant Staphylococcus aureus (MRSA) . N'ime iri afọ ole na ole gara aga, n'ihi evolushọn nje bacteria na iji ọgwụ nje eme ihe n'ụzọ gabigara ókè, nguzogide S. Aureus na ọgwụ ọjọọ na-arị elu, na-ebute mmụba zuru ụwa ọnụ na ọnụ ọgụgụ ọrịa MRSA.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
 Treatment of severe skin and soft tissue infections: a review 29278528 
NIH
To review the salient features of the management of severe skin and soft tissue infections (SSTIs), including toxic shock syndrome, myonecrosis/gas gangrene, and necrotizing fasciitis.